康辰药业
(603590)
| 流通市值：57.10亿 | | | 总市值：57.39亿 |
| 流通股本：1.58亿 | | | 总股本：1.59亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 357,362,222.51 | 332,573,095.7 | 307,862,872.04 | 366,314,713.38 |
| 交易性金融资产 | 430,110,053.09 | 500,428,236.12 | 481,357,458.29 | 391,050,361.08 |
| 应收票据及应收账款 | 271,546,025.98 | 272,298,551.97 | 320,215,399.29 | 345,252,441.13 |
| 应收账款 | 271,546,025.98 | 272,298,551.97 | 320,215,399.29 | 345,252,441.13 |
| 应收款项融资 | 3,595,912.6 | 5,790,985.2 | 4,545,270 | 4,275,154.97 |
| 预付款项 | 12,631,223.85 | 9,489,192.68 | 16,193,704.28 | 11,889,335.14 |
| 其他应收款合计 | 76,027,978.11 | 76,068,970.25 | 32,370,406.59 | 32,803,577.54 |
| 存货 | 58,960,915.31 | 54,470,412.52 | 59,295,393.08 | 69,521,027.12 |
| 其他流动资产 | 112,419,158.36 | 144,409,393.69 | 129,860,067.6 | 156,443,276.99 |
| 流动资产合计 | 1,322,653,489.81 | 1,395,528,838.13 | 1,351,700,571.17 | 1,377,549,887.35 |
| 非流动资产: | | | | |
| 长期股权投资 | 47,614,322.61 | 47,183,925.12 | 404,575,579.96 | 48,610,808.32 |
| 其他权益工具投资 | 891,131,473.02 | 885,501,569.07 | 527,111,409.35 | 696,604,008.15 |
| 其他非流动金融资产 | 92,627,331.64 | 92,552,916.74 | 88,370,621.84 | 88,253,178.36 |
| 固定资产 | 306,597,713.6 | 312,765,392.53 | 320,457,931.75 | 191,098,987 |
| 在建工程 | 83,171,108.01 | 81,732,025.78 | 82,133,203.49 | 216,114,155.24 |
| 生产性生物资产 | 258,250 | 295,750 | 325,000 | 362,500 |
| 使用权资产 | 7,773,281.9 | 9,361,004.41 | 10,948,726.92 | 12,536,449.42 |
| 无形资产 | 830,865,007.03 | 833,374,634.3 | 835,533,644.65 | 838,008,635.73 |
| 开发支出 | 318,920,702.16 | 307,611,058.47 | 288,187,934.67 | 263,629,184.63 |
| 长期待摊费用 | 338,504.03 | 390,795.46 | 443,086.89 | 495,378.32 |
| 递延所得税资产 | 16,840,847.06 | 21,361,256.77 | 21,464,424.1 | 21,806,951.78 |
| 其他非流动资产 | 158,383,980.03 | 107,336,000.91 | 117,304,600.68 | 116,745,575.43 |
| 非流动资产合计 | 2,754,522,521.09 | 2,699,466,329.56 | 2,696,856,164.3 | 2,494,265,812.38 |
| 资产总计 | 4,077,176,010.9 | 4,094,995,167.69 | 4,048,556,735.47 | 3,871,815,699.73 |
| 流动负债: | | | | |
| 短期借款 | 266,155,596.15 | 253,453,114.36 | 211,050,281.36 | 182,390,695.81 |
| 应付票据及应付账款 | 38,771,897.52 | 31,198,305.18 | 52,761,246.05 | 51,592,173.07 |
| 应付账款 | 38,771,897.52 | 31,198,305.18 | 52,761,246.05 | 51,592,173.07 |
| 预收款项 | 50,000,000 | 50,000,000 | 50,000,000 | - |
| 合同负债 | 3,921,086.92 | 5,954,896.84 | 6,574,909.29 | 2,354,059.34 |
| 应付职工薪酬 | 23,564,935.87 | 50,008,665.01 | 35,012,226.25 | 27,962,295.98 |
| 应交税费 | 7,735,173.43 | 11,692,127.72 | 19,314,650.37 | 11,977,452.28 |
| 其他应付款合计 | 34,324,737.79 | 47,753,013.83 | 49,019,744.13 | 48,075,538.8 |
| 一年内到期的非流动负债 | 9,290,337.6 | 9,248,551.47 | 9,191,155.55 | 9,123,866.99 |
| 其他流动负债 | 48,739.78 | 138,782.64 | 106,612.67 | 47,380.12 |
| 流动负债合计 | 433,812,505.06 | 459,447,457.05 | 433,030,825.67 | 333,523,462.39 |
| 非流动负债: | | | | |
| 长期借款 | 54,014,215 | 54,283,615 | 55,305,312 | 55,574,712 |
| 租赁负债 | 1,456,525.8 | 3,174,505.87 | 4,880,258.79 | 6,564,008 |
| 递延收益 | 40,591,096.21 | 41,867,797.33 | 37,582,706.77 | 38,623,037.9 |
| 递延所得税负债 | 39,535,229.33 | 39,737,375.57 | 32,631,455.41 | 31,718,308.21 |
| 非流动负债合计 | 135,597,066.34 | 139,063,293.77 | 130,399,732.97 | 132,480,066.11 |
| 负债合计 | 569,409,571.4 | 598,510,750.82 | 563,430,558.64 | 466,003,528.5 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 159,010,477 | 159,010,477 | 159,356,477 | 159,356,477 |
| 资本公积 | 949,822,477.68 | 948,769,539.25 | 952,526,567.1 | 950,547,293.83 |
| 减:库存股 | 75,926,603.3 | 32,858,206.04 | 19,192,990 | 19,192,990 |
| 其他综合收益 | 25,927,014.78 | 21,141,596.42 | -17,103,260.12 | -12,230,834.16 |
| 盈余公积 | 80,000,000 | 80,000,000 | 80,000,000 | 80,000,000 |
| 未分配利润 | 2,082,426,425.12 | 2,035,212,850.81 | 2,041,365,198.51 | 1,960,291,997.3 |
| 归属于母公司股东权益合计 | 3,221,259,791.28 | 3,211,276,257.44 | 3,196,951,992.49 | 3,118,771,943.97 |
| 少数股东权益 | 286,506,648.22 | 285,208,159.43 | 288,174,184.34 | 287,040,227.26 |
| 股东权益合计 | 3,507,766,439.5 | 3,496,484,416.87 | 3,485,126,176.83 | 3,405,812,171.23 |
| 负债和股东权益合计 | 4,077,176,010.9 | 4,094,995,167.69 | 4,048,556,735.47 | 3,871,815,699.73 |
| 公告日期 | 2026-04-23 | 2026-04-23 | 2025-10-30 | 2025-08-28 |
| 审计意见(境内) | | 标准无保留意见 | | |